Preferred Label : ALK/ROS1 Inhibitor TGRX-326;
NCIt definition : An orally bioavailable inhibitor of the receptor tyrosine kinases anaplastic lymphoma
kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity.
Upon oral administration, ALK/ROS1 inhibitor TGRX-326 targets, binds to and inhibits
the activity of ALK and ROS1, which leads to the disruption of ALK- and ROS1-mediated
signaling and the inhibition of cell growth in ALK- and ROS1-expressing tumor cells.
ALK belongs to the insulin receptor superfamily and plays an important role in nervous
system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation
and gene rearrangements are associated with a variety of tumor cell types. ROS1, overexpressed
in certain cancer cells, plays a key role in cell growth and survival of cancer cells.;
Molecule name : TGRX 326; TGRX-326;
NCI Metathesaurus CUI : CL1794263;
Origin ID : C189066;
UMLS CUI : C5706533;
Semantic type(s)
- concept_is_in_subset
- has_target
